Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
BRIDGEWATER, N.J., March 06, 2018 -- Clinical Genomics, a leading provider of colorectal cancer testing and solutions, is pleased to announce that its CLIA licensed and CAP accredited New Jersey laboratory is now licensed by the Florida Agency for Healthcare Administration to offer services for patients residing within the state of Florida. Clinical Genomics is the sole provider of COLVERA™, a liquid biopsy ctDNA assay used to detect residual disease and recurrent disease in patients previously diagnosed with colorectal cancer.
Dr. Lawrence LaPointe, President and CEO of Clinical Genomics, said, “This approval allows Florida doctors to offer COLVERA to their patients in one of the largest US oncology markets.”
“We are pleased to make available our world-class liquid biopsy testing to colorectal cancer surgeons and medical oncologists for the nearly 10,000 patients in Florida who are treated for colorectal cancer each year,” added Dr. John P. Alsobrook II, DABCC, FACB, Laboratory Site Director and Vice President of Operations for Clinical Genomics Pathology.
About Clinical Genomics
Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer. Clinical Genomics products span the full spectrum of colorectal cancer testing, including InSure® FIT™, a fecal immunochemical test for screening in healthy adults, InSure® ONE™, a one sample FIT used to detect lower GI bleeding, and COLVERA™, a proprietary liquid biopsy blood test identifying circulating tumor DNA for detection of residual disease and early detection of recurrence in post-treatment patients. Clinical Genomics is committed to developing and delivering solutions that provide physicians and their patients with information to help guide earlier and better treatment decisions in cancer care management. Clinical Genomics continues to apply its proprietary innovation in molecular pathology to commercialize other diagnostic tools in other cancer types.
Media Contact:
Patty Jenkins
[email protected]
+ 1.412.376. 2770
